ICU Medical account plan
IV therapy safety solutions
At a glance
ICU Medical makes infusion systems, IV consumables and vital care products, with FY2025 revenues of $2,231.3 million and about 13,000 employees.
ICU Medical (Nasdaq: ICUI), founded in 1984 and based in San Clemente, California, develops, manufactures and sells infusion therapy, vascular access and vital care products: IV pumps and safety software, IV sets, needlefree connectors, catheters, closed system transfer devices, and respiratory, anesthesia, monitoring and temperature management products. It has approximately 13,000 employees in over 35 countries and customers in over 100 countries. FY2025 total revenues were $2,231.3 million, net income was $0.7 million and gross margin rose to 36.8%. Most global revenue comes from products made in Costa Rica and Mexico.
Business units
Consumables
50% of FY2025 revenue ($1,109.2 million)IV sets, needlefree connectors, catheters and closed system transfer devices. Revenue grew 6.8% in 2025 and 4.7% to a record $298.4 million in Q3 2026.
Infusion Systems
31% of FY2025 revenue ($684.2 million)IV pumps (including Plum Duo and Plum Solo, Medfusion syringe and CADD ambulatory pumps) and safety software. Q3 2026 revenue rose 10.7% to $192.5 million on LVP pump competitive wins and early rollovers.
Vital Care
19% of FY2025 revenue ($437.9 million)Respiratory, anesthesia, monitoring and temperature management products. Revenue fell 36.6% in 2025 after the IV Solutions deconsolidation and 10.9% to $69.5 million in Q3 2026 on lower Pain Management volumes; parts of the portfolio are under strategic review.
Strategic priorities
- Gross margin expansion
- A 43% gross margin target by the exit of 2027 is maintained; Q3 2026 gross margin was 41.9%.
- Infusion pump platform
- Grow Infusion Systems at least high single digits in 2026, file a revised 510(k) for the MedFusion 5000 syringe pump, follow with CADD, and use European authorization of Plum Duo and Solo.
- Resolve FDA quality issues
- Close out the 2025 FDA warning letter covering Medfusion 4000 and CADD Solis VIP, with $60 million to $80 million planned in 2026 for Smiths Medical restructuring, integration and quality spending.
- Free cash flow and capital return
- Year-to-date free cash flow reached $173 million against an original $150 million target; with net leverage at 2x, returning capital is under consideration for the new year.
- Portfolio pruning in Vital Care
- Exit unprofitable SKUs and certain Japanese surgical commodities, with several work streams on strategic outcomes for parts of Vital Care.
Latest results
Q3 2026 total revenues were $560.4 million against $537.0 million in Q3 2025 (presented on the call as $556 million, +5% organic), and net income was $26.8 million against a net loss of $3.4 million. Gross margin rose to 41.9% from 37.4%, helped by $10.4 million of IEEPA tariff refunds and price increases; adjusted EBITDA was $114 million and adjusted EPS $2.44 versus $2.03. U.S. revenue rose to $361.2 million while EMEA fell to $90.7 million. Full-year results are expected towards the higher end of $415 million to $435 million adjusted EBITDA and $8.60 to $9 adjusted EPS.
Investments and deals
- IV Solutions joint venture
- On May 1, 2025 ICU sold a 60% interest in IV Solutions to Otsuka Pharmaceutical Factory America for $211.2 million and keeps 40% of Otsuka ICU Medical LLC, which announced an over $500 million expansion of its Austin, Texas plant funded by OPF.
- Capex
- 2026 capex now expected at about $75 million (previously $85 million to $100 million), covering Costa Rica, Europe, Mexico and U.S. plants and pumps placed outside the U.S.
- Debt reduction
- Term loans fell to $1.2 billion at September 30, 2026 after Term Loan B prepayments of $45.3 million (Q2) and $75.3 million (Q3).
Challenges and risks
- Tariffs
- Most products are made in Costa Rica and Mexico and imported into the U.S.; 2025 incremental reciprocal tariffs were $33.6 million, and the CFO warned that Section 232 tariffs could be hard to overcome for 2027 margins.
- FDA warning letter and pump clearances
- ICU withdrew its July 2025 510(k) applications for the new Medfusion and CADD pumps after FDA requested additional testing and plans to resubmit.
- Vital Care decline
- Vital Care fell 10% organic in Q3 2026, hit by the legacy Smiths logistics consolidation.
- Input and logistics costs
- A $10 per barrel oil rise costs about $3 million a year.
What leadership says
“the 43% started as 45%, it was net down 2% for tariffs.”
“We know returning capital can be attractive on a thin share base, and our external M&A needs are minimal”
“The market needs ICU Medical to be an innovative, reliable supplier”
“We have a complete platform solution that will anchor this segment for the next 10-plus years as the product life cycles are incredibly long.”
Where a supplier can help
- Quality and regulatory support
- The open FDA warning letter and the need for additional pump testing ahead of 510(k) resubmission favour testing, quality-systems and regulatory consulting suppliers.
- Manufacturing cost and margin
- The 43% gross margin target and tariff pressure make automation, procurement and plant efficiency offers for Costa Rica, Mexico and U.S. sites relevant.
- Supply chain and tariff mitigation
- Tariff exposure and the Smiths logistics consolidation that hit Vital Care create room for logistics, trade compliance and sourcing partners.
- Pump rollout services
- LVP pump competitive wins and rollovers, plus European launch of Plum Duo and Solo, need installation, training and integration services for hospital customers.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like ICU Medical?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- ICU Medical, Inc. Annual Report on Form 10-K for the fiscal year ended December 31, 2025
- ICU Medical (San Clemente, California; founded 1984; Nasdaq: ICUI) develops, manufactures and sells infusion therapy, vascular access and vital care products: IV pumps and safety software, IV sets, needlefree connectors, catheters, closed system transfer devices, and respiratory, anesthesia, monitoring and temperature management products. Approximately 13,000 employees in over 35 countries; customers in over 100 countries.
- FY2025 total revenues were $2,231.3 million (2024: $2,382.0 million); net income was $0.7 million after net losses of $117.7 million in 2024 and $29.7 million in 2023. Gross margin rose to 36.8% from 34.6%.
- Three business units, one reportable segment: Consumables $1,109.2 million (50% of revenue, +6.8%), Infusion Systems $684.2 million (31%, +4.9%), Vital Care $437.9 million (19%, -36.6% after the IV Solutions deconsolidation).
- On May 1, 2025 ICU sold a 60% interest in its IV Solutions business to Otsuka Pharmaceutical Factory America (OPF) for $211.2 million and keeps 40% of the joint venture, Otsuka ICU Medical LLC; it still sells the JV's IV Solutions in the U.S. and Canada. $200.0 million of the proceeds repaid Term Loan A.
- Plum Duo and Plum Solo precision infusion pumps received FDA 510(k) clearance in April 2025; 510(k) applications for next-generation Medfusion syringe and refreshed CADD ambulatory pumps were filed in July 2025, tied to an April 2025 FDA warning letter on the Oakdale, Minnesota (ex-Smiths Medical) facility.
- Tariffs are a top risk: the majority of global revenues come from products made in Costa Rica and Mexico and imported into the U.S.; 2025 incremental reciprocal tariffs were $33.6 million, and a Section 232 investigation into medical consumables imports was opened in September 2025.
- Balance sheet: term loans of $1.3 billion at year-end 2025 after $290.0 million of prepayments in 2025 and an October 2025 refinancing ($750.0 million Term Loan A, $500.0 million revolver); cash $308.0 million.
- 2026 plans: capex of $85 million to $100 million (Costa Rica, Europe, Mexico, U.S. plants and pumps placed outside the U.S.) and $60 million to $80 million for Smiths Medical restructuring, integration and quality spending.
- Leadership: Vivek Jain, CEO and Chairman (since 2014); Brian Bonnell, CFO; Christian Voigtlander, COO; Daniel Woolson, President (since October 2024).
- ICU Medical, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 total revenues $560.4 million vs. $537.0 million in Q3 2025; nine-month revenues $1,642.3 million vs. $1,690.6 million (the 2025 period still included IV Solutions until May 1, 2025).
- Q3 net income $26.8 million vs. a net loss of $3.4 million a year earlier; nine-month net income $76.1 million.
- Q3 by business unit: Consumables $298.4 million (+4.7%), Infusion Systems $192.5 million (+10.7%, driven by about $16 million more LVP hardware volume), Vital Care $69.5 million (-10.9%, lower Pain Management volumes).
- Gross margin 41.9% in Q3 vs. 37.4%, helped by $10.4 million of IEEPA tariff refunds and about 1.5 points from price increases; nine-month IEEPA refunds total $29.2 million and no further material refunds are expected.
- U.S. revenue rose to $361.2 million in Q3 from $307.1 million; EMEA fell to $90.7 million from $115.1 million.
- Debt: term loans of $1.2 billion at September 30, 2026 after $45.3 million (Q2) and $75.3 million (Q3) Term Loan B prepayments; cash $301.8 million; Moody's now Ba3, S&P BB, all outlooks stable.
- 2026 capex now expected at about $75 million (previously $85 million to $100 million); the Otsuka ICU Medical JV announced an over $500 million expansion of its Austin, Texas IV Solutions plant, funded by OPF.
- Open issue: the 2025 FDA warning letter on Medfusion 4000 and CADD Solis VIP; ICU withdrew its July 2025 510(k) applications after FDA requested additional testing and plans to resubmit.
- ICU Medical (ICUI) Q3 2026 earnings call transcript
- Q3 2026 revenue (as presented on the call) was $556 million, +5% organic and +4% reported; adjusted gross margin just over 42%, adjusted EBITDA $114 million (20.5% margin), adjusted EPS $2.44 vs. $2.03.
- Consumables grew 5% to record sales; IV systems grew 11% to a record quarter, led by LVP pumps through competitive wins and early rollovers; Vital Care fell 10% organic, hit by the legacy Smiths logistics consolidation.
- Guidance: full year expected towards the higher end of $415 million to $435 million adjusted EBITDA and $8.60 to $9 adjusted EPS; Infusion Systems at least high single digits for 2026; capex guidance cut from $85 million to $75 million.
- Year-to-date free cash flow $173 million, above the original $150 million target, helped by $31 million of IEEPA tariff refunds; about $80 million of debt repaid in Q3 and net leverage at 2x.
- Gross margin target of 43% by the exit of 2027 is maintained; Jain: "the 43% started as 45%, it was net down 2% for tariffs."
- Product pipeline: revised 510(k) for the MedFusion 5000 syringe pump to be filed in the next few weeks, CADD a couple of months behind; European authorization for Plum Duo and Solo; consumables launches in 2027.
- Capital allocation: leverage target reached; Jain says external M&A needs are minimal and returning capital can be attractive on a thin share base, to be decided in the new year.
- Risk flagged by CFO Brian Bonnell: Section 232 tariffs could be hard to overcome for 2027 margins.
- ICU Medical (ICUI) Q1 2026 earnings call transcript
- Q1 2026 revenue was $526 million: +1% organic, -12% reported because of the IV Solutions deconsolidation into the Otsuka JV; adjusted EBITDA $99 million (flat), adjusted EPS $1.97 vs. $1.72 (+15%), gross margin above 41%.
- Consumables +5% reported and 2% organic (January softened after a late-2025 flu spike); IV Systems +8% reported and 6% organic, a record quarter in pumps led by LVP; Vital Care -14% organic as unprofitable SKUs are exited.
- FDA asked for more testing (larger sample size, more set configurations) on the new Medfusion and CADD pumps; ICU will finish Medfusion first. The 2021 Smiths warning letter has been resolved; a 2025 warning letter still covers a subset of products.
- Guidance unchanged; tariff expense was $10 million in Q1 (about 2% of adjusted revenue); a $10 per barrel oil rise costs about $3 million a year, offset by lower Section 122 tariffs and faster efficiencies. Full-year free cash flow target close to $150 million.
- Vital Care portfolio under review: exit of certain Japanese surgical commodities, and "several different work streams" on strategic outcomes for parts of Vital Care.
- Capital allocation: leverage within half a turn of the 2x target; Jain says external M&A needs are minimal and returning capital can be attractive on a thin share base.
Questions about ICU Medical
What does ICU Medical do?
It makes infusion therapy products (IV pumps and safety software), IV consumables such as sets, connectors and catheters, and vital care products for respiratory, anesthesia, monitoring and temperature management.
What is ICU Medical's revenue?
FY2025 total revenues were $2,231.3 million; Q3 2026 revenues were $560.4 million.
How many employees does ICU Medical have?
Approximately 13,000 employees in over 35 countries.
Who leads ICU Medical?
Vivek Jain is CEO and Chairman (since 2014), with CFO Brian Bonnell, COO Christian Voigtlander and President Daniel Woolson.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)